Avastin Use May Be Overly Restricted By Medicare ESA Proposal – Genentech
Executive Summary
CMS' proposal to place limits on erythropoiesis-stimulating agents in the cancer setting might restrict even proper uses of the cancer drug Avastin (bevacizumab), Genentech says
You may also be interested in...
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances
AHRQ Comparative Effectiveness Funding Doubled In 2008 Budget Bills
Funding for medical product comparative effectiveness research within the HHS Agency for Healthcare Research and Quality would increase to $30 million in fiscal year 2008 appropriations legislation pending in both the House and Senate